NB Bancorp, Inc. financials

  1. Home
  2. Financials
  3. NBBK
NBBK CIK 0001979330

Source: EDGAR filings · Built 2026-06-02T03:37:58Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2023
Free Cash Flow 57.38M 41.25M 50.03M 31.22M
Net Debt -385.86M -350.66M -261.82M -145.50M
Return on Equity (ROE) 5.86% 5.51% 1.30% 8.74%
Return on Assets (ROA) 0.72% 0.82% 0.22% 0.84%
Debt-to-Equity 0.03× 0.02× 0.01× 0.03×
Effective Tax Rate 29.28% 28.10% 17.05% 17.38%
Cash Conversion Ratio 1.21× 1.02× 5.38× 1.32×
Accruals Ratio -0.00× -0.00× -0.01× -0.00×
CapEx Coverage 17.79× 22.28× 18.46× 4.67×
Free Cash Flow Per Share $1.52 $1.05 $1.19 —

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2023
P/E Trailing (Diluted) 14.79× 16.88× 58.48× —
P/FCF 13.00× 17.25× 11.29× —
FCF Yield 7.69% 5.80% 8.85% —
P/B 1.06× 1.01× 0.76× —

Income Statement

Concept FY 2025FY 2024FY 2023FY 2023
Income Tax Expense (Benefit) 20.83M 16.47M 2.02M 6.32M
Net Income (Loss) Attributable to Parent 50.30M 42.15M 9.82M 30.07M
Earnings Per Share, Basic $1.34 $1.07 $0.23 —
Weighted Average Number of Shares Outstanding, Basic 37.41M 39.39M 42.02M —
Earnings Per Share, Diluted $1.34 $1.07 $0.23 —
Weighted Average Number of Shares Outstanding, Diluted 37.63M 39.39M 42.02M —

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2023
Assets 7.01B 5.16B 4.53B 3.59B
Liabilities 6.15B 4.39B 3.78B 3.25B
Stockholders' Equity Attributable to Parent 858.93M 765.17M 757.96M 344.06M
Common Stock, Shares, Outstanding 45.77M 42.71M 42.71M 0

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2023
Net Cash Provided by (Used in) Operating Activities 60.79M 43.19M 52.90M 39.71M
Payments to Acquire Property, Plant, and Equipment 3.42M 1.94M 2.87M 8.50M
Net Cash Provided by (Used in) Investing Activities -519.05M -546.44M -831.62M -667.99M
Payments for Repurchase of Common Stock 77.13M — — —
Net Cash Provided by (Used in) Financing Activities 502.00M 594.52M 894.77M 317.77M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (NBBK CIK 0001979330), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

IKT

INHIBIKASE THERAPEUTICS, INC.

RZLV

Rezolve AI plc

BFC

Bank First Corp